CA
NZ
UK
AU
IND
US
Randall Allen Roewe, Executive Vice President and Chief Risk Officer of First Financial Bankshares Inc (NASDAQ:FFIN), filed a Form 4 on August 18, 2026, disclosing multiple transactions in common stock and derivative securities dated August 14 and August 16, 2026.
A Form 4 filed with the SEC on August 18, 2026, disclosed that Melody Birmingham, Executive Vice President and Group President, Utilities at NiSource Inc. (NYSE:NI), sold 37,509.173 shares of NiSource common stock on August 14, 2026.
Wolfgang Pusch, President of the BMID Group at Bruker Corp (NASDAQ:BRKR), filed a Form 4 on August 18, 2026, reporting equity awards granted on August 15, 2026, and an open-market sale of common stock on August 17, 2026.
Thomas Bures, Chief Accounting Officer of Bruker Corp, filed a Form 4 on August 18, 2026, disclosing the acquisition of 4,035 restricted stock units in Bruker Corp common stock on August 15, 2026.
Burkhard Prause, President and CEO of Bruker BeST, filed a Form 4 on August 18, 2026, disclosing the acquisition of restricted stock units and stock options in Bruker Corporation common stock on August 15, 2026.
Grant Brown, Senior Vice President and Chief Financial Officer of Qorvo, Inc. (NASDAQ:QRVO), filed a Form 4 on August 18, 2026, disclosing the sale of 5,179 shares of common stock on August 17, 2026.
A Form 4 filed with the SEC on August 18, 2026 discloses that Philip Chesley, Senior Vice President of High Performance Analog at Qorvo, Inc. (NASDAQ:QRVO), sold 5,487 shares of common stock on August 17, 2026.
A statement of changes in beneficial ownership was filed on August 18, 2026, disclosing that Brent Pfeiffenberger, President and CEO of Century Therapeutics, Inc., had 31,172 shares of common stock withheld by the issuer on August 14, 2026, to satisfy tax withholding obligations connected …
A Form 4 filed with the SEC on August 18, 2026 discloses that Todd G. Schwartz, Chief Executive Officer and Director of OppFi Inc. (NYSE:OPFI), purchased 3,500 shares of Class A Common Stock on August 17, 2026 through the TGS Revocable Trust.
Frank Stokes, Chief Financial Officer of Castle Biosciences Inc., filed a Form 4 with the SEC on August 18, 2026, disclosing the sale of 24,908 shares of common stock on August 14, 2026.
Please wait processing your request...